Disclosed herein are methods of treating a patient in need of therapy for prostate cancer comprising delivering a β-radiation-emitting composition into the prostatic vasculature. In some embodiments, an absorbed dose of 60 Gy to 200 Gy is delivered to the prostate. In some embodiments, the β-radiation-emitting composition is delivered into the arterial vasculature of the prostate via a catheter. In some embodiments, the β-radiation-emitting composition comprises a suspension of the β-radiation-emitting particles in an aqueous liquid.

A method of treating a cancer in a mammalian subject afflicted with the cancer, includes administering to the subject an immune checkpoint inhibitor, and administering to the subject a pentaaza macrocyclic ring complex corresponding to the formula (I) below, prior to, concomitantly with, or after administration of the immune checkpoint inhibitor, to increase the response of the cancer to the immune checkpoint inhibitor.

##STR00001##

The invention relates to an ultrasound contrast agent (UCA) comprising an outer shell and a gas core. The gas core is filled with oxygen, and the outer shell comprises a first surfactant and a second surfactant. The invention also relates to a method of making an oxygen-filled UCA and delivering oxygen to a local area of a subject's body. The method comprises injecting a composition comprising an oxygen-filled UCA of the invention into the subject's body; directing ultrasound radiation to the local area in an intensity sufficient to rupture the UCA.

Methods of potentiating chemotherapy or radiotherapy are disclosed. The methods comprise administering to a subject in need of chemotherapeutic or radiotherapeutic treatment an effective amount of a composition comprising biocompatible nanoparticles under conditions in which the nanoparticles alter one or more cell regulatory mechanisms in cells in which the nanoparticles are localised or other cells. Then one or more doses of a chemotherapeutic or radiotherapeutic treatment are administered to the subject either concurrently with or after the nanoparticles have altered the one or more cell regulatory mechanisms in the cells in which the nanoparticles are localised or other cells. Also disclosed are methods of enhancing the effects of chemotherapy or radiotherapy on a cell population, methods of increasing the amount of strand breaks in DNA in a cell, and methods of inducing cancer cell death.

Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.

A method for inducing abscopal, complete or partial response to radiotherapy comprising administering isoflavone compounds and irradiating with a cytotoxic dose of ionising radiation so that fewer than all of the plurality of tumours are irradiated.

The present invention relates to the field of human health and more particularly concerns nanoparticles for use as a therapeutic vaccine in the context of radiotherapy in a subject suffering of a cancer, in particular of a metastatic cancer or of a liquid cancer.

The world is plagued with several viruses some of which have prevention and treatment tools available, while every so often a new strain will show up without sensitivity to existing drugs. The present invention provides plant-based flavonoid pharmaceutical compositions for inhibition of kinases, particularly phosphatidylinositol-4-kinases (PI4Kiiiβ), AAK1, BIKE, GAK and other transcription factors required for viral entry, replication and survival, and consequent for prevention and treatment of RNA viruses including but not limited to adenoviruses, alphaviruses, coronaviruses, enteroviruses, flaviviruses, hepatitis, herpes, influenza viruses, measles, picornaviruses, vesicular stomatitis and associated disorders. A method for synthesizing the flavonoids and formulation into therapeutic products are also disclosed.

The present invention provides a novel radiosensitizer or anti-cancer chemotherapy sensitizer. In particular, the invention provides a radiosensitizer or anti-cancer chemotherapy sensitizer that can relieve the irritation of an affected area caused by hydrogen peroxide, is safe when injected into a human body, and can delay or reduce the degradation of hydrogen peroxide and thereby can efficiently exert a radiation sensitizing effect and an anti-cancer chemotherapy sensitizing effect. The radiosensitizer or anti-cancer chemotherapy sensitizer comprises a combination of (a) hydrogen peroxide and (b) hyaluronic acid or salt thereof.

Materials and methods for enhancing the effectiveness of proton radiation therapy (e.g., high linear energy transfer (LET) proton radiation therapy) against tumor cells are provided herein.